Ledger.Open graph →
SEC Form D · Amendment · filed August 23, 2022

Praesidia Biotherapeutics, Inc

Offering
$10.0M
Sold
$4.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
ARLINGTON, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (14)

Martin Lehr · Philadelphia, PADirectorRobert J. Bitterman · Marlborough, MADirectorDal C. Reid · Amarillo, TXExec · DirectorCurtis A. Lockshin · Marlborough, MAExecPradip Majumder · Arlington, MAExecShawn Titcomb · Lauderdale by the Sea, FLDirectorSohang Chatterjee · Arlington, MAExec · DirectorJohn Ripple · Cambridge, MADirectorDouglas J. Crozier · Amarillo, TXDirectorClayton M. Olson · VANCOUVER, British Columbia, CanadaExecJohn Ripple · Cambridge, MADirectorKevin Logan · San Francisco, CADirectorMichael Blady · VANCOUVER, British Columbia, CanadaDirectorRobert A. Ferrara · Marlborough, MAExec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗